ZYBT

+ Watchlist + Portfolio

Zhengye Biotechnology Holding Limited

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.85
52-Week Range: $0.62 – $13.08
Market Cap: $89.57M
P/E (TTM): —
EPS (TTM): -0.22
Dividend Yield: —

Advanced Metrics

Price/Book: 2.42
PEG Ratio: —
Return on Equity: -25.17%
Return on Assets: -9.48%
Gross Margin: 20.51%
Operating Margin: -77.04%
Profit Margin: -59.97%
Current Ratio: 1.14
Debt/Equity: 0.24
Total Debt: $75.08M
Free Cash Flow: $39.58M
Revenue Growth: -40.90%
Earnings Growth: —
Enterprise Value: $167.73M

ZYBT Income statement, annual periods, in CNY
CNY	FY2022	FY2023	FY2024	FY2025
Revenue	$260.27M	$211.65M	$186.36M	$116.36M
Cost of Revenue	$112.39M	$94.14M	$95.06M	$92.49M
Gross Profit	$147.88M	$117.51M	$91.30M	$23.87M
Research & Development	$13.42M	$11.90M	$12.79M	$18.01M
Selling, General & Admin	$58.89M	$64.33M	$63.84M	$74.92M
Operating Expenses	$81.79M	$69.87M	$74.12M	$92.12M
Operating Income	$66.09M	$47.64M	$17.17M	-$68.25M
EBITDA	$85.55M	$72.10M	$42.60M	-$42.52M
Pretax Income	$63.91M	$43.76M	$14.39M	-$71.87M
Income Tax	$8.17M	$6.25M	$924.00K	$11.10M
Net Income	$46.73M	$31.46M	$11.31M	-$69.78M
Diluted EPS	0.99	0.67	0.24	—
Diluted Shares	47.17M	47.17M	47.17M	—

ZYBT Balance Sheet statement, annual periods, in CNY
CNY	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$9.75M	$15.07M	$18.60M	$50.33M
Receivables	$134.25M	$99.42M	$85.16M	$18.48M
Inventory	$55.42M	$58.30M	$58.22M	$39.17M
Current Assets	$214.31M	$189.24M	$177.57M	$137.42M
Total Assets	$519.67M	$499.89M	$493.25M	$436.47M
Current Liabilities	$152.23M	$150.23M	$135.91M	$120.48M
Long-Term Debt	$9.99M	$9.99M	$4.80M	$8.85M
Total Debt	$64.88M	$89.85M	$86.43M	$75.08M
Total Liabilities	$162.81M	$160.62M	$140.71M	$129.76M
Retained Earnings	$65.77M	$38.38M	$48.15M	-$21.63M
Shareholders' Equity	$296.50M	$272.85M	$283.96M	$249.85M
Working Capital	$62.08M	$39.01M	$41.66M	$16.94M
Net Debt	$55.13M	$74.78M	$67.83M	$24.32M

ZYBT Cash Flow statement, annual periods, in CNY
CNY	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$17.34M	$48.18M	$41.05M	$13.33M
Capital Expenditure	-$27.33M	-$11.60M	-$27.77M	-$12.63M
Free Cash Flow	-$9.99M	$36.58M	$13.27M	$703.00K
Depreciation & Amortisation	$18.80M	$23.91M	$24.16M	$25.95M
Investing Cash Flow	-$27.33M	-$11.77M	-$27.66M	-$12.63M
Financing Cash Flow	$13.46M	-$18.98M	-$22.13M	$32.31M
Dividends Paid	-$21.43M	-$39.45M	-$16.02M	$0.00
Net Change in Cash	$3.46M	$17.44M	-$8.75M	$33.01M

ZYBT Balance Sheet statement, quarterly periods, in CNY
CNY	Q4 2024	Q2 2025	Q4 2025
Cash & Equivalents	$18.60M	$45.61M	$50.33M
Receivables	$85.16M	$87.91M	$18.48M
Inventory	$58.22M	$53.55M	$39.17M
Current Assets	$177.57M	$201.45M	$137.42M
Total Assets	$493.25M	$504.63M	$436.47M
Current Liabilities	$135.91M	$134.84M	$120.48M
Long-Term Debt	$4.80M	$4.70M	$8.85M
Total Debt	$86.43M	$85.76M	$75.08M
Total Liabilities	$140.71M	$139.53M	$129.76M
Retained Earnings	$48.15M	$26.48M	-$21.63M
Shareholders' Equity	$283.96M	$298.92M	$249.85M
Working Capital	$41.66M	$66.61M	$16.94M
Net Debt	$67.83M	$40.16M	$24.32M

Market Snapshot

About

Zymergen was a biotechnology company that used machine learning and automation to engineer microbes for novel materials and products. The company aimed to revolutionize material science by programming biology to create sustainable alternatives to petroleum-based chemicals and materials. Zymergen has faced significant business challenges and may no longer be actively operating.